OKLAHOMA CITY — Wheeler Bio , an Oklahoma City -based contract development and biomanufacturing organization, has announced a strategic partnership with Mitsubishi Corporation to accelerate business development across the Asia-Pacific region.

The partnership positions Mitsubishi Corporation as Wheeler’s exclusive commercialization partner throughout Japan, South Korea, India, Singapore, Taiwan and China. Beyond participating in Wheeler’s Series A-1 financing round, Mitsubishi will leverage its extensive regional network and industry relationships to connect Asia-Pacific biotech innovators with Wheeler’s U.S.-based development and cGMP manufacturing capabilities.

Wheeler Bio specializes in antibody-based therapeutics through its AI/ML-enabled ModularCMC platform, which strea

See Full Page